Press releases

BARCELONA, Spain, April 14, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 12 weeks post-treatment (SVR₁₂), regardless of the presence of baseline resistance-associated variants (RAVs).¹ These late-breaking data from a post-hoc analysis of five completed Phase 3 clinical trials will be presented today at The International Liver Congress™ (ILC) 2016 in Barcelona, Spain.

NORTH CHICAGO, Ill., April 11, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Venclexta™ (venetoclax) tablets for patients diagnosed with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy.¹ The FDA approved this indication under accelerated approval based on overall response rate, and continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. The FDA approved Venclexta as a first-in-class, oral, once-daily medicine¹ that selectively inhibits the BCL-2 protein.¹ The BCL-2 protein blocks apoptosis (programmed cell death) of cells, including some cancer cells, and can be overexpressed in CLL cells.¹ Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group. It is marketed collaboratively by the companies in the U.S. and by AbbVie outside of the U.S.

NORTH CHICAGO, Ill., April 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2016 financial results on Thursday, April 28, 2016, before the market opens.

NORTH CHICAGO, Ill., April 6, 2016 /PRNewswire/ -- AbbVie today announced that the 2016 AbbVie CF Scholarship, which honors and supports young adults with cystic fibrosis (CF) as they pursue higher education, is now accepting applications. Undergraduate and graduate students can apply for the scholarship from now until May 27, 2016 at 10:00 a.m. U.S. central time by visiting www.AbbVieCFScholarship.com.

NORTH CHICAGO, Ill., April 5, 2016 /PRNewswire/ -- AbbVie today announced a partnership with celebrity dietitian Joy Bauer to raise awareness about the importance of a healthy diet and lifestyle for people with a little-known gastrointestinal (GI) condition called exocrine pancreatic insufficiency (EPI). The renowned dietitian and television personality drew upon the expertise from her 25-year career to develop a guide containing nutrition tips and healthy recipes for this community of patients. The nutrition guide, along with additional information on EPI can be found at www.identifyepi.com/joybauer.

NORTH CHICAGO, Ill., April 4, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for HUMIRA® (adalimumab) for the treatment of moderately to severely active Crohn's disease in pediatric patients (from six years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.

NORTH CHICAGO, Ill., March 30, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for presentation at The International Liver Congress™ (ILC) 2016 in Barcelona, Spain, April 13-17, including real-world data that support clinical trial results seen in AbbVie's development program with VIEKIRAX^® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA^® (dasabuvir tablets). Abstracts presented will further expand scientific knowledge of VIEKIRAX and EXVIERA in genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infected patients, including those with compensated cirrhosis (Child-Pugh A).

NORTH CHICAGO, Ill., March 8, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Thursday, March 17, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 8 a.m. Central time.

NORTH CHICAGO, Ill. and INGELHEIM, Germany, March 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. AbbVie and Boehringer Ingelheim also are evaluating the potential of this biologic therapy in Crohn's disease, psoriatic arthritis and asthma. In addition to the anti-IL-23 antibody, AbbVie gains rights to an anti-CD-40 antibody, BI 655064, currently in Phase 1 development. Boehringer Ingelheim will retain responsibility for further development of BI 655064, and AbbVie may elect to advance the program after completion of certain undisclosed clinical achievements.

NORTH CHICAGO, Ill., March 4, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA^® (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).¹ The approval is based on data from the randomized, multi-center, open-label Phase 3 RESONATE™-2 (PCYC-1115) trial, which evaluated the use of IMBRUVICA versus chlorambucil in 269 treatment-naïve patients with CLL or small lymphocytic lymphoma (SLL) aged 65 years or older. The RESONATE-2 data were previously presented at the American Society of Hematology (ASH) Annual Meeting in December 2015 and also simultaneously published in The New England Journal of Medicine. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc.